Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines

Biochemical Pharmacology

Volumn 58, Issue 11, 1999, Pages 1713-1721

  Lee, Sang I ^a   Brown, Mary Kay ^a   Eastman, Alan ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cell cycle checkpoints; Cisplatin; K252a; Staurosporine; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; CAFFEINE; CISPLATIN; K 252A; K 252B; KT 5720; KT 5823; KT 5926; MIDOSTAURIN; NOCODAZOLE; PROTEIN P53; STAUROSPORINE; STAUROSPORINE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL;

ALKALOIDS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CISPLATIN; DRUG INTERACTIONS; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0032729120     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00258-0     Document Type: Article

References (27)

1. Rauth A.M. Evidence for dark-reactivation of ultraviolet light damage in mouse L cells. Radiat Res. 31:1967;121-138.
2. Lau C.C., Pardee A.B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA. 79:1982;2942-2946.
3. Demarcq C., Bunch R.T., Creswell D., Eastman A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ. 5:1994;983-993.
4. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
5. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
6. 1 checkpoint-competent cells. Cancer Res. 55:1995;1639-1642.
7. 2 delay. Cancer Res. 55:1995;1643-1648.
8. Fan S., Smith M.L., Rivet D.J. II, Duba D., Zhan Q., Kohn K.W., Fornace A.J. Jr, O'Connor P.M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55:1995;1649-1654.
9. Osborne R.J., Merlo G.R., Mitsudomi T., Venesio T., Liscia D.S., Cappa A.P.M., Chiba I., Takahashi T., Nau M.M., Callahan R., Minna J.D. Mutations in the p53 gene in primary human breast cancers. Cancer Res. 51:1991;6194-6198.
10. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer mutation and nuclear exclusion . Proc Natl Acad Sci USA. 89:1992;7262-7266.
11. 2-checkpoint inhibitor. Clin Cancer Res. 2:1996;791-797.
12. Bunch R.T., Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates the cisplatin-induced S phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 8:1997;779-788.
13. 2 checkpoint function in cancer cells with disrupted p53 . J Natl Cancer Inst. 88:1996;956-965.
14. Hill D.L., Tillery K.F., Rose L.M., Posey C.F. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Cancer Chemother Pharmacol. 35:1994;89-92.
15. Sausville E.A. A Phase I Trial of Continuous Infusion UCN-01 in Patients with Refractory Neoplasms (NCI Protocol T95-0052). 1996;National Cancer Institute, Bethesda, MD.
16. 1 phase of the cell cycle. Proc Natl Acad Sci USA. 88:1991;7580-7584.
17. Bruno S., Ardelt B., Skierski J.S., Traganos F., Darzynkiewicz Z. Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res. 51:1992;470-473.
18. Schlegel R., Pardee A.B. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science. 232:1986;1264-1266.
19. The BIOMOL Catalog and Handbook, Edn 6, p, 63. BIOMOL Research Laboratories, Plymouth Meeting, PA, 1997.
20. Lawrie A.M., Noble M.E.M., Tunnah P., Brown N.R., Johnson L.N., Endicott J.A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol. 4:1997;796-801.
21. Takahashi I., Asano K., Kawamoto I., Nakano H. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation. J Antibiot (Tokyo). 42:1989;564-570.
22. Takahashi I., Saitoh Y., Yoshida M., Sano H., Nakano H., Morimoto M., Tamaoki T. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot (Tokyo). 42:1989;571-576.
23. Meyer T., Regenass U., Fabbro D., Alteri E., Rosel J., Muller M., Caravatti G., Matter A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 43:1989;851-856.
24. Abraham I., Wolf C.L., Sampson K.E., Labordie A.L., Shelly J.A., Aristoff P.A., Skulnick H.I. K252a, KT5720, KT5926 and U98017 support paclitaxel (taxol)-dependent cells and synergize with paclitaxel. Cancer Res. 54:1994;5889-5894.
25. Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H., Elledge S.J. Conservation of the Chk1 checkpoint pathway in mammals Linkage of DNA damage to Cdk regulation through Cdc25 . Science. 277:1997;1497-1501.
26. Furnari B., Rhind N., Russell P. Cdc25 mitotic inducer targeted by Chk1 DNA damage checkpoint kinase. Science. 277:1997;1495-1497.
27. Boddy M.N., Furnari B., Mondesert O., Russell P. Replication checkpoint enforced by kinases Cds1 and Chk1. Science. 280:1998;909-912.